https://www.selleckchem.com/pr....oducts/geneticin-g41
The "six-and-twelve" (612) score is a new hepatocellular carcinoma (HCC) prognostic index designed for recommended transarterial chemoembolization (TACE) candidates. Quick and easy to use by the sum of tumor size (cm) and number, this model identifies three groups with different survival time (the sum is ≤ 6; or 6 but ≤ 12; or 12); a survival benefit with TACE can be expected for HCC patients with a score not exceeding twelve. Recently, Wang ZW et al showed that the "612" model was the best system corr
Like
Comment
Share
